Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448718 · ClinicalTrials.gov registry record · Phase 2
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
A Phase 2 study of Metastatic Urothelial Cancer, sponsored by Matthew Galsky.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 7
- Study locations
NCT03448718 is a Phase 2 study of Metastatic Urothelial Cancer that has completed, run by Matthew Galsky. The registered enrollment target is 19 participants, below the 649-participant average among 5 other Metastatic Urothelial Cancer trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT03448718, a Phase 2 study of Metastatic Urothelial Cancer, has completed, sponsored by Matthew Galsky.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a single arm open label multi-institutional phase II trial of olaparib monotherapy in subjects with metastatic urothelial cancer harboring somatic DNA damage response (DDR) alterations. The primary objective of the study is to estimate the objective response rate (per RECIST 1.1) to treatment with olaparib.
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (7)
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Michigan
- Karmanos Cancer Center (Wyane State University) - Detroit
New York
- Icahn School of Medicine at Mount Sinai - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Tennessee
- Vanderbilt-Ingran Cancer Center - Nashville
Utah
- Huntsman Cancer Institute University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03448718
The ClinicalTrials.gov registry entry for NCT03448718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 649-participant average among 5 other Metastatic Urothelial Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Matthew Galsky, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Urothelial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.
NCT03448718 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Illinois, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT03448718 about?
NCT03448718 is a clinical study titled "Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations". This is a single arm open label multi-institutional phase II trial of olaparib monotherapy in subjects with metastatic urothelial cancer harboring somatic DNA damage response (DDR) alterations. The primary objective of the study is to estimate the objective response rate (per RECIST 1.1) to treatmen...
What is the current status of trial NCT03448718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-04-17. Estimated completion is 2021-10-15.
What conditions does trial NCT03448718 study?
This clinical trial studies the following conditions: Metastatic Urothelial Cancer.
What interventions are being tested in trial NCT03448718?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT03448718?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03448718 being conducted?
This trial has 7 study locations across Illinois, Maryland, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
RECRUITING · Phase 2
-
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
RECRUITING · Phase 2
-
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
COMPLETED · Phase 2
-
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.